Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INDP | Indaptus Therapeutics, Inc.

Index	-	P/E	-	EPS (ttm)	-1.75	Insider Own	2.30%	Shs Outstand	8.40M	Perf Week	-19.82%
Market Cap	21.25M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	134.28%	Shs Float	5.76M	Perf Month	4.23%
Income	-14.60M	PEG	-	EPS next Q	-0.55	Inst Own	6.90%	Short Float / Ratio	0.39% / 1.14	Perf Quarter	41.88%
Sales	-	P/S	-	EPS this Y	8.00%	Inst Trans	13.90%	Short Interest	0.02M	Perf Half Y	49.72%
Book/sh	2.22	P/B	1.22	EPS next Y	2.10%	ROA	-57.10%	Target Price	8.00	Perf Year	-2.17%
Cash/sh	2.51	P/C	1.08	EPS next 5Y	-	ROE	-63.60%	52W Range	1.25 - 4.08	Perf YTD	86.90%
Dividend	-	P/FCF	-	EPS past 5Y	57.90%	ROI	-	52W High	-33.58%	Beta	1.17
Dividend %	-	Quick Ratio	9.40	Sales past 5Y	-	Gross Margin	-	52W Low	116.80%	ATR	0.28
Employees	6	Current Ratio	9.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.13	Volatility	13.82% 8.73%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	16.80%	Profit Margin	-	Rel Volume	2.23	Prev Close	3.33
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	Payout	-	Avg Volume	19.79K	Price	2.71
Recom	2.00	SMA20	-10.97%	SMA50	10.65%	SMA200	34.98%	Volume	44,072	Change	-18.62%

Sep-19-23 08:00AM	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 (GlobeNewswire) +7.34%
Sep-06-23 08:05AM	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:00AM	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.83%
Aug-10-23 08:45AM	Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 (GlobeNewswire) +22.78%
Aug-07-23 08:00AM	Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer (GlobeNewswire)
08:00AM	Loading…
Jun-15-23 08:00AM	Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-31-23 08:30AM	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-11-23 07:00AM	Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.30%
May-09-23 08:00AM	Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform (GlobeNewswire) -16.18%
May-01-23 08:00AM	Indaptus Therapeutics Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -8.74%
Apr-20-23 04:05PM	Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023 (GlobeNewswire) -7.83%
Apr-19-23 09:28AM	UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire) +23.17%
08:05AM	Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Apr-17-23 08:00AM	Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform (GlobeNewswire)
08:00AM	Loading…
Mar-22-23 08:00AM	Indaptus Therapeutics to Present at the Investor Summit Conference (GlobeNewswire)
Mar-17-23 08:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.34%
Mar-15-23 08:05AM	Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023 (GlobeNewswire)
Mar-13-23 08:05AM	Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Mar-07-23 08:05AM	Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Feb-14-23 08:00AM	Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Feb-07-23 08:05AM	Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-13-22 07:30AM	Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors (GlobeNewswire) +9.52%
Nov-10-22 04:05PM	Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-18-22 07:00AM	Indaptus Therapeutics to Present at the LD Micro Main Event XV (GlobeNewswire)
Sep-06-22 09:02AM	Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-08-22 08:00AM	Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-09-22 07:00AM	Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-03-22 07:00AM	Indaptus Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
07:00AM	Loading…
May-19-22 07:00AM	Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors (GlobeNewswire) +18.80%
May-18-22 04:15PM	Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:00AM	Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 12:20PM	Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders placed bullish bets worth US$2.4m in the last 12 months (Simply Wall St.)
Apr-20-22 07:00AM	Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit (GlobeNewswire)
Mar-23-22 07:00AM	Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-21-22 07:00AM	Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 07:00AM	Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit (GlobeNewswire) +6.73%
Mar-07-22 07:00AM	Indaptus Therapeutics to Present at 34th Annual ROTH Conference (GlobeNewswire) -7.67%
Jan-14-22 09:38AM	Stratos Wealth Partners, LTD. Buys PowerShares QQQ Trust Ser 1, WisdomTree U.S. ... (GuruFocus.com)
Jan-05-22 07:00AM	Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire) -8.55%
Jan-03-22 07:00AM	Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer (GlobeNewswire) +8.25%
Dec-01-21 08:00AM	Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors (GlobeNewswire) -10.08%
Nov-15-21 07:00AM	Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -9.88%
Nov-04-21 10:51AM	Bullish insiders at Indaptus Therapeutics, Inc. (NASDAQ:INDP) loaded up on US$775k of stock earlier this year (Simply Wall St.)
Sep-15-21 07:00AM	Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent (GlobeNewswire) +52.05%

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Glen R.	10% Owner	Aug 14	Buy	2.34	23,934	56,006	1,190,400	Aug 16 06:01 PM
Anderson Glen R.	10% Owner	Aug 11	Buy	2.12	35,064	74,336	1,166,466	Aug 16 06:01 PM
Anderson Glen R.	10% Owner	Aug 10	Buy	1.94	44,354	86,047	1,131,402	Aug 16 06:01 PM
Litchev Boyan Vesselinov	Chief Medical Officer	Dec 01	Buy	1.87	500	935	1,150	Dec 19 09:06 PM
Litchev Boyan Vesselinov	Chief Medical Officer	Nov 22	Buy	1.83	500	915	650	Dec 19 09:06 PM
Meckler Jeffrey A	CEO and Director	Nov 21	Buy	1.90	9,600	18,240	75,374	Nov 22 08:00 AM
Meckler Jeffrey A	CEO and Director	Nov 18	Buy	1.76	400	705	65,774	Nov 22 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INDP | Indaptus Therapeutics, Inc.

Upgrade your FINVIZ experience